Zelmac Pooled Study Results May Not Be Reflective Of Efficacy - FDA

Pooling of efficacy data across three trials for Novartis' irritable bowel syndrome therapy Zelmac may not be appropriate because of mixed outcomes among the trials, FDA indicated in briefing documents prepared for the Gastrointestinal Drugs Advisory Committee meeting June 26.